Einloggen

Thematische Bibliographien / Tenofovir alafenamide

Inhaltsverzeichnis

Zeitschriftenartikel
Dissertationen
Bücher
Buchteile
Konferenzberichte

Auswahl der wissenschaftlichen Literatur zum Thema „Tenofovir alafenamide“

Autor: Grafiati

Veröffentlicht am 28. Juni 2021

Zuletzt aktualisiert am 17. Februar 2022

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Tenofovir alafenamide" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Tenofovir alafenamide"

1

Gibson, Amanda K., Bhavik M. Shah, Puja H. Nambiar und Jason J. Schafer. „Tenofovir Alafenamide“. Annals of Pharmacotherapy 50, Nr. 11 (28.07.2016): 942–52. http://dx.doi.org/10.1177/1060028016660812.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Mothobi, Nomvuyo Z., Jeffrey Masters und Deborah J. Marriott. „Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV-infected patient“. Therapeutic Advances in Infectious Disease 5, Nr. 5 (10.07.2018): 91–95. http://dx.doi.org/10.1177/2049936118785497.

Der volle Inhalt der Quelle

Annotation:

A case of tenofovir-induced Fanconi syndrome in a patient receiving antiretroviral therapy for HIV infection, with resolution of the related electrolyte abnormalities upon switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate, is reported. Tenofovir alafenamide fumarate, a novel prodrug of tenofovir containing significantly lower doses of tenofovir than tenofovir disoproxil fumarate, has been associated with a favourable renal profile compared to tenofovir disoproxil fumarate. Generally, the rare complication of tenofovir disoproxil fumarate–induced Fanconi syndrome is managed by cessation of tenofovir. There are limited reports of the impact of a switch strategy from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate, which may be necessary in patients unable to discontinue tenofovir.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Lengauer, Hannes, Damjan Makuc, Damjan Šterk, Franc Perdih, Arthur Pichler, Tina Trdan Lušin, Janez Plavec und Zdenko Časar. „Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates“. Pharmaceutics 12, Nr. 4 (10.04.2020): 342. http://dx.doi.org/10.3390/pharmaceutics12040342.

Der volle Inhalt der Quelle

Annotation:

Tenofovir alafenamide fumarate (TAF) is the newest prodrug of tenofovir that constitutes several drug products used for the treatment of HIV/AIDS. Although the solid-state properties of its predecessor tenofovir disoproxil fumarate have been investigated and described in the literature, there are no data in the scientific literature on the solid state properties of TAF. In our report, we describe the preparation of two novel polymorphs II and III of tenofovir alafenamide monofumarate (TA MF2 and TA MF3). The solid-state structure of these compounds was investigated in parallel to the previously known tenofovir alafenamide monofumarate form I (TA MF1) and tenofovir alafenamide hemifumarate (TA HF). Interestingly, the single-crystal X-ray diffraction of TA HF revealed that this derivative exists as a co-crystal form. In addition, we prepared a crystalline tenofovir alafenamide free base (TA) and its hydrochloride salt (TA HCl), which enabled us to determine the structure of TA MF derivatives using 15N-ssNMR (15N-solid state nuclear magnetic resonance). Surprisingly, we observed that TA MF1 exists as a mixed ionization state complex or pure salt, while TA MF2 and TA MF3 can be obtained as pure co-crystal forms.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Wassner, Chanie, Nicole Bradley und Yuman Lee. „A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide“. Journal of the International Association of Providers of AIDS Care (JIAPAC) 19 (01.01.2020): 232595822091923. http://dx.doi.org/10.1177/2325958220919231.

Der volle Inhalt der Quelle

Annotation:

HIV is a serious chronic medical condition. Significant improvements in antiretroviral therapy have led to a transformation in its management. No curative treatment is available for HIV, and lifelong therapy is required with a combination of agents to control viral replication and prevent complications. Some of the older agents are notorious for many side effects, making patient compliance difficult, which is critical to preventing HIV resistance. Tenofovir is one of the newer, more tolerable, nucleotide reverse transcriptase inhibitors on the market; is a mainstay of many antiretroviral therapy combinations; and is now available in 2 different formulations, tenofovir disoproxil fumarate (TDF) and, the more recent, tenofovir alafenamide (TAF). These 2 formulations have very different pharmacokinetics, which seem to affect their efficacy and safety. This manuscript provides insight into the history of TDF and TAF development, their unique pharmacokinetics and pharmacology, clinically important adverse effects, monitoring, interactions, resistance, review of clinical studies, and guideline recommendations and clinical applications for tenofovir’s various indications.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Álvarez, Hortensia, und Josep M. Llibre. „Fanconi Syndrome and Tenofovir Alafenamide“. Annals of Internal Medicine 171, Nr. 8 (15.10.2019): 598. http://dx.doi.org/10.7326/l19-0476.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Bahr, Nathan C., und Sri G. Yarlagadda. „Fanconi Syndrome and Tenofovir Alafenamide“. Annals of Internal Medicine 171, Nr. 8 (15.10.2019): 599. http://dx.doi.org/10.7326/l19-0477.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Khawaja, Akif A., Kirk A. Taylor, Andrew O. Lovell, Mark Nelson, Brian Gazzard, Marta Boffito und Michael Emerson. „HIV Antivirals Affect Endothelial Activation and Endothelial-Platelet Crosstalk“. Circulation Research 127, Nr. 11 (06.11.2020): 1365–80. http://dx.doi.org/10.1161/circresaha.119.316477.

Der volle Inhalt der Quelle

Annotation:

Rationale: People living with HIV on effective antiretroviral therapy are at increased risk of cardiovascular complications, possibly due to off-target drug effects. Some studies have associated antiretroviral therapy with increased risk of myocardial infarction and endothelial dysfunction, but a link between endothelial function and antiretrovirals has not been established. Objective: To determine the effects of antiretrovirals in common clinical use upon in vitro endothelial function to better understand cardiovascular risk in people living with HIV. Methods and Results: Human umbilical cord vein endothelial cells or human coronary artery endothelial cells were pretreated with the antiretrovirals abacavir sulphate (ABC), tenofovir disoproxil fumarate, or tenofovir alafenamide. Expression of adhesion molecules, ectonucleotidases (CD39 and CD73), tissue factor (TF), endothelial-derived microparticle (EMP) numbers and phenotype, and platelet activation were evaluated by flow cytometry. TF and ectonucleotidase activities were measured using colourimetric plate-based assays. ABC-treated endothelial cells had higher levels of ICAM (intercellular adhesion molecule)-1 and TF expression following TNF (tumor necrosis factor)-α stimulation. In contrast, tenofovir disoproxil fumarate and tenofovir alafenamide treatment gave rise to greater populations of CD39 + CD73 + cells. These cell surface differences were also observed within EMP repertoires. ABC-treated cells and EMP had greater TF activity, while tenofovir disoproxil fumarate- and tenofovir alafenamide-treated cells and EMP displayed higher ectonucleotidase activity. Finally, EMP isolated from ABC-treated cells enhanced collagen-evoked platelet integrin activation and α-granule release. Conclusions: We report differential effects of antiretrovirals used in the treatment of HIV upon endothelial function. ABC treatment led to an inflammatory, prothrombotic endothelial phenotype that promoted platelet activation. In contrast, tenofovir disoproxil fumarate and tenofovir alafenamide conferred potentially cardioprotective properties associated with ectonucleotidase activity. These observations establish a link between antiretrovirals and specific functional effects that provide insight into cardiovascular disease in people living with HIV.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Biagi, MJ, CA Schriever, TD Chiampas, SM Michienzi, MC Patel, JD Young und ME Badowski. „Development of gynecomastia following initiation of bictegravir/emtricitabine/tenofovir alafenamide“. International Journal of STD & AIDS 31, Nr. 4 (10.02.2020): 380–82. http://dx.doi.org/10.1177/0956462419895665.

Der volle Inhalt der Quelle

Annotation:

Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a recently approved single-tablet antiretroviral regimen and is recommended as a first-line agent. No cases of gynecomastia were reported in clinical trials. We report development of ultrasound-confirmed gynecomastia in a previously antiretroviral-naïve patient approximately two months after starting BIC/FTC/TAF, which resolved ten weeks after discontinuing bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) based therapy.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Yamada, Hiroyuki, Takuma Yonemura, Takanori Nemoto, Noriko Ninomiya und Shin Irie. „Pharmacokinetics of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects“. Clinical Pharmacology in Drug Development 8, Nr. 4 (16.10.2018): 511–20. http://dx.doi.org/10.1002/cpdd.623.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Satsangi, Sandeep. „To use entecavir, tenofovir disoproxil fumarate or tenofovir alafenamide“. European Journal of Gastroenterology & Hepatology 30, Nr. 6 (Juni 2018): 689–90. http://dx.doi.org/10.1097/meg.0000000000001104.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Dissertationen zum Thema "Tenofovir alafenamide"

1

Gomez, Camacho Mario Alberto [Verfasser], und Johannes [Akademischer Betreuer] Bogner. „Eine retrospektive Analyse der Gewichtsveränderungen bei HIV-positiven Patienten, die von einer Tenofovir-Disoproxil-Fumarat (TDF) zu einer Tenofovir-Alafenamid-Fumarat (TAF)-haltigen Therapie in einer deutschen Universitätsklinik im Zeitraum 2015-2017 wechseln / Mario Alberto Gomez Camacho ; Betreuer: Johannes Bogner“. München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2021. http://d-nb.info/1238518761/34.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Schulz, Sebastian Peter [Verfasser], Roland M. [Akademischer Betreuer] Schmid, Roland M. [Gutachter] Schmid und Christoph [Gutachter] Spinner. „Über die Veränderung der Insulinsensitivität in gesunden, freiwilligen Probanden nach 14-tägiger Einnahme von Tenofovir alafenamid-haltiger antiretroviraler Medikation : Die TAF-IR-Studie / Sebastian Peter Schulz ; Gutachter: Roland M. Schmid, Christoph Spinner ; Betreuer: Roland M. Schmid“. München : Universitätsbibliothek der TU München, 2020. http://d-nb.info/1216626227/34.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Halodová, Veronika. „In vitro a ex vivo studium lékových interakcí antivirotik na střevních membránových transportérech“. Master's thesis, 2021. http://www.nusl.cz/ntk/nusl-446286.

Der volle Inhalt der Quelle

Annotation:

Charles University Faculty of Pharmacy in Hradec Králové Department of Pharmacology & Toxicology Student: Veronika Halodová Supervisor: doc. PharmDr. Lukáš Červený, Ph.D. Title of diploma thesis: In vitro and ex vivo study of drug-drug interactions of antivirals on intestinal membrane transporters Tenofovir (TFV) is the first-line agent in the treatment of hepatitis B virus (HBV) infection for patients aged over 12 years and one of the first-line choices for the combination antiretroviral therapy (cART) of infections caused by human immunodeficiency virus (HIV). Two commercially available prodrugs have been developed for oral administration of TFV, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide fumarate (TAF). These prodrugs increase TFV membrane permeability and oral bioavailability. One of the factors that can affect the bioavailability of orally administrated drugs is active transport mediated by efflux transporters, mainly by P-glycoprotein (ABCB1, P-gp) and Breast cancer resistance protein (ABCG2, BCRP). It has been already proved that TDF and TAF are substrates of both of these transporters. The goal of this diploma thesis was to use in vitro and ex vivo models of intestinal barrier to assess the impact of the efflux transporters on TDF and TAF transport in the intestine and on their...

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Bücher zum Thema "Tenofovir alafenamide"

1

Blokdijk, G. J. Tenofovir Alafenamide; Third Edition. CreateSpace Independent Publishing Platform, 2018.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Bell, Tanvir K. Musculoskeletal Complications of HIV. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190493097.003.0043.

Der volle Inhalt der Quelle

Annotation:

Vitamin D levels have been observed to be low in HIV-infected patients. If replacement of low vitamin D is warranted, supplementation is done with vitamin D2 or D3. HIV-infected patients may be at higher risk for osteopenia, osteoporosis, and fragility fractures. Tenofovir alafenamide has been shown to produce less bone loss compared to tenofovir disoproxil fumarate. Muscle disorders can be debilitating in HIV-infected patients. Myopathies can have a range of presentation from myalgias to rhabdomyolysis. HIV myopathy is a rare proximal muscle disorder that can occur in HIV-infected patients. Antiretroviral drugs, including zidovudine and raltegravir, can cause myopathy and elevated creatine kinase.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Majid, Adrian, und Bruce L. Gilliam. Future Antiretrovirals, Immune-Based Strategies, and Therapeutic Vaccines. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190493097.003.0023.

Der volle Inhalt der Quelle

Annotation:

Highly active antiretroviral therapy remains the mainstay of treatment for patients chronically infected with HIV. Novel drugs, both within existing classes and new ones, are in various stages of development and testing. New medications within existing classes of antiretroviral agents are in clinical trials and will likely offer activity against resistant HIV-1 strains and provide alternatives for combination pill therapy. Novel therapeutics including oral attachment inhibitors and monoclonal antibody treatments continue to show efficacy against HIV-1 and progress in clinical trials. Tenofovir alafenamide is a prodrug that produces higher intracellular levels of tenofovir diphosphate with likely less renal and bone toxicity. Among traditional classes of HIV treatment, both doravirine (a non-nucleoside reverse transcriptase inhibitor) and cabotegravir (an integrase strand inhibitor) are newer agents with activity against resistant virus. Maturation inhibitors are a new class of treatment that block protease cleavage, leading to the release of an immature virion.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Buchteile zum Thema "Tenofovir alafenamide"

1

„DESCOVY (Tenofovir Alafenamide + Emtricitabine)“. In Antibiotics Manual, 122–23. Chichester, UK: John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119220787.ch55.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

„ODEFSEY (Tenofovir alafenamide + Emtricitabine + Rilpivirine)“. In Antibiotics Manual, 266–67. Chichester, UK: John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119220787.ch122.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

„VEMLIDY (Tenofovir Alafenamide Fumarate (TAF))“. In Antibiotics Manual, 408–9. Chichester, UK: John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119220787.ch188.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

„GENVOYA (Tenofovir Alafenamide + Emtricitabine + Elvitegravir + Cobicistat)“. In Antibiotics Manual, 178–80. Chichester, UK: John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119220787.ch81.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "Tenofovir alafenamide"

1

Camean-Castillo, M., E. Rios-Sanchez, MD Gil-Sierra, MP Briceño-Casado, FJ Salmeron-Navas, S. Fenix-Caballero, J. Diaz-Navarro, C. Martinez-Diaz, EJ Alegre-Del Rey und JM Borrero-Rubio. „2SPD-005 Economical analysis of tenofovir alafenamide versus tenofovir-disoproxil fumarate“. In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.45.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Gutiérrez Lorenzo, M., J. Urda Romacho, D. Rubio Calvo, MA Castro Vida und CM Pinto Nieto. „4CPS-259 One year with bictegravir/emtricitabine/tenofovir alafenamide“. In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.91.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Caraffa, A., A. Colicchio, L. Gasperoni, G. Selvetti, I. Tommasini, E. Zuccarini und M. Mancini. „4CPS-060 Prescription analysis of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in a third level hospital“. In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.161.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Taberner Bonastre, P., L. Vallez Valero, SM Cano Marrón, T. Puig Ganau, B. Amoros Folguera, FI Torres Bondia und JA Schoenenberger Arnaiz. „5PSQ-042 Modification on fasting lipid and renal parameters in patients switching from tenofovir disoproxil to tenofovir alafenamide“. In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.475.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Petersen, J., C. Hoffmann, A. Rieke, M. Cornberg, H. Hinrichsen, WP Hofmann, K. Simon et al. „Real World Experience of Prescribing Tenofovir Alafenamide for Chronic Hepatitis B Patients in Germany“. In Viszeralmedizin 2019. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1695324.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Gracia, R., JM Vinuesa, I. Sanjoaquin, T. Salvador, MDP Pardo, MA Alcácera, A. Apesteguia, MJ Crusells, S. Letona und M. Gimeno-Gracia. „4CPS-062 Patients with darunavir/cobicistat/emtricitabine/tenofovir alafenamide treatment in a third level hospital“. In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.163.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Lik Yuen Chan, Henry, Wai Kay Seto, Maria Buti, Namiki Izumi, Young-Suk Lim, Jia-Horng Kao, Adrian Streinu-Cercel et al. „IDDF2019-ABS-0168 Bone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF)“. In International Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-iddfabstracts.277.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

De Luca, A., G. Zaccaro, A. Ascani und S. Murachelli. „5PSQ-145 Analysis of therapeutic regimens containing tenofovir disoproxil and tenofovir alafenamide in the 4 year period 2016–2019 in a research, hospitalisation and healthcare institute“. In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.264.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Yuen Chan, Henry Lik, Young-Suk Lim, Wai Kay Seto, Qin Ning, Kosh Agarwal, Harry LA Janssen, Calvin O. Pan et al. „IDDF2020-ABS-0061 Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB)“. In Abstracts of the International Digestive Disease Forum (IDDF), 22–23 November 2020, Hong Kong. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2020. http://dx.doi.org/10.1136/gutjnl-2020-iddf.144.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Chan, Henry Lik-Yuen, Maria Buti, Robert Flisiak, Stephen Ryder, Adrian Streinu-Cercel, John F. Flaherty, Anuj Gaggar et al. „IDDF2018-ABS-0107 Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF)“. In International Digestive Disease Forum (IDDF) 2018, Hong Kong, 9–10 June 2018. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2018. http://dx.doi.org/10.1136/gutjnl-2018-iddfabstracts.208.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!